Cardiovascular Drugs and Therapy

, Volume 29, Issue 2, pp 137–146 | Cite as

Correlation Between SNPs in Candidate Genes and VerifyNow-Detected Platelet Responsiveness to Aspirin and Clopidogrel Treatment

  • Hanbin Cui
  • Shaoyi Lin
  • Xiaomin Chen
  • Wenhui Gao
  • Xiaojing Li
  • Honglin Zhou
  • Weiping Du
  • Shenghuang Wang
  • Ruochi Zhao



Patients with high on-treatment platelet reactivity (HPR) against aspirin or clopidogrel are at increased risk for adverse cardiovascular events. In this study, we explored the predictive value of common SNPs for the on-treatment platelet reactivity (OPR) against aspirin and clopidogrel assessed by VerifyNow assays.


This study recruited 286 Han Chinese individuals undergoing antiplatelet treatment, including 159 cases with aspirin only (100 mg/day) and 127 cases with dual therapy (aspirin 100 mg/day plus clopidogrel 75 mg/day) for at least 2 weeks. The OPR against aspirin and clopidogrel were assessed by VerifyNow Aspirin (ARU) and P2Y12 assays (PRU), respectively. Genotyping for the selected 25 SNPs within 11 genes and 2 GWAS loci was carried out by ABI multiplex SNaPshot method.


The results indicated that rs4244285 (CYP2C19) and rs342293 (7q22.3) were significantly associated with PRU value (both P < 0.01). As for the OPR to aspirin, a weak statistical significance was observed in rs5445 (GNB3) (P = 0.049) and rs5758 (TBXA2R) (P = 0.045). After adjusting for the covariates including gender, age and smoking, carriers of allele A of rs4244285 remained as a strong predictor for HPR against clopidogrel.


The current study suggests that common SNPs may predict OPR against clopidogrel as assessed by VerifyNow P2Y12, but are less likely to respond against aspirin as assessed by VerifyNow Aspirin.


SNP High on-treatment platelet reactivity Aspirin Clopidogrel VerifyNow assay 


  1. 1.
    Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J. 2006;27:647–54.CrossRefPubMedGoogle Scholar
  2. 2.
    Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol. 2006;47:27–33.CrossRefPubMedGoogle Scholar
  3. 3.
    Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol. 2004;24:1980–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;336:195–8.CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J. 2007;154:221–31.CrossRefPubMedGoogle Scholar
  6. 6.
    Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109:3171–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol. 2008;51:1404–11.CrossRefPubMedGoogle Scholar
  8. 8.
    Wong S, Morel-Kopp MC, Chen Q, Appleberg M, Ward CM, Lewis DR. Overcoming aspirin resistance: increased platelet inhibition with combination aspirin and clopidogrel and high dose aspirin therapy in aspirin resistant patients with peripheral vascular disease. Thromb Haemost. 2006;95:1042–3.PubMedGoogle Scholar
  9. 9.
    Angiolillo DJ, Capranzano P, Ferreiro JL, Ueno M, Capodanno D, Dharmashankar K, et al. Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. Thromb Haemost. 2011;106:253–62.CrossRefPubMedGoogle Scholar
  10. 10.
    Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the gravitas randomized trial. JAMA. 2011;305:1097–105.CrossRefPubMedGoogle Scholar
  11. 11.
    Collet JP, Cuisset T, Range G, Cayla G, Elhadad S, Pouillot C, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367:2100–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Muller U, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the trigger-pci (testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. J Am Coll Cardiol. 2012;59:2159–64.CrossRefPubMedGoogle Scholar
  13. 13.
    Aradi D, Storey RF, Komocsi A, Trenk D, Gulba D, Kiss RG, et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J. 2014;35:209–15.CrossRefPubMedCentralPubMedGoogle Scholar
  14. 14.
    Aradi D, Collet JP, Mair J, Plebani M, Merkely B, Jaffe AS, et al. Platelet function testing in acute cardiac care - is there a role forprediction or prevention of stent thrombosis and bleeding? Thromb Haemost. 2015;113:221–30.CrossRefPubMedGoogle Scholar
  15. 15.
    Campo G, Miccoli M, Tebaldi M, Marchesini J, Fileti L, Monti M, et al. Genetic determinants of on-clopidogrel high platelet reactivity. Platelets. 2011;22:399–407.CrossRefPubMedGoogle Scholar
  16. 16.
    Feher G, Feher A, Pusch G, Lupkovics G, Szapary L, Papp E. The genetics of antiplatelet drug resistance. Clin Genet. 2009;75:1–18.CrossRefPubMedGoogle Scholar
  17. 17.
    Li Y, Wang WJ, Cao H, Lu J, Wu C, Hu FY, et al. Genetic association of foxo1a and foxo3a with longevity trait in han chinese populations. Hum Mol Genet. 2009;18:4897–904.CrossRefPubMedCentralPubMedGoogle Scholar
  18. 18.
    Palacajornsuk P, Halter C, Isakova V, Tarnawski M, Farmar J, Reid ME, et al. Detection of blood group genes using multiplex snapshot method. Transfusion. 2009;49:740–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Blais N, Pharand C, Lordkipanidze M, Sia YK, Merhi Y, Diodati JG. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, verifynow system, platelet count drop, thromboelastography (teg) and urinary 11-dehydrothromboxane b(2). Thromb Haemost. 2009;102:404–11.PubMedGoogle Scholar
  20. 20.
    Nielsen HL, Kristensen SD, Thygesen SS, Mortensen J, Pedersen SB, Grove EL, et al. Aspirin response evaluated by the verifynow aspirin system and light transmission aggregometry. Thromb Res. 2008;123:267–73.CrossRefPubMedGoogle Scholar
  21. 21.
    Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Harmsze AM, Hackeng CM, Ten Berg JM. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart. 2011;97:983–90Google Scholar
  22. 22.
    Ko YG, Suh JW, Kim BH, Lee CJ, Kim JS, Choi D, et al. Comparison of 2 point-of-care platelet function tests, verifynow assay and multiple electrode platelet aggregometry, for predicting early clinical outcomes in patients undergoing percutaneous coronary intervention. Am Heart J. 2011;161:383–90.CrossRefPubMedGoogle Scholar
  23. 23.
    Gaglia MA, Torguson R, Pakala R, Xue Z, Sardi G, Suddath WO, et al. Correlation between light transmission aggregometry, verifynow p2y12, and vasp-p platelet reactivity assays following percutaneous coronary intervention. J Interv Cardiol. 2011;24:529–34.CrossRefPubMedGoogle Scholar
  24. 24.
    Madsen EH, Saw J, Kristensen SR, Schmidt EB, Pittendreigh C, Maurer-Spurej E. Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, verifynow, and thrombelastography in patients undergoing percutaneous coronary intervention. Clin Chem. 2010;56:839–47.CrossRefPubMedGoogle Scholar
  25. 25.
    Kim IS, Jeong YH, Kang MK, Koh JS, Park Y, Hwang SJ, et al. Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the verifynow p2y12 assay. J Thromb Thrombolysis. 2010;30:486–95.CrossRefPubMedGoogle Scholar
  26. 26.
    Patti G, Pasceri V, Vizzi V, Ricottini E, Di Sciascio G. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the antiplatelet therapy for reduction of myocardial damage during angioplasty-bleeding study). Am J Cardiol. 2011;107:995–1000.CrossRefPubMedGoogle Scholar
  27. 27.
    Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dorrler K, et al. Cytochrome p450 2c19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J. 2009;30:916–22.CrossRefPubMedGoogle Scholar
  28. 28.
    Jang JS, Cho KI, Jin HY, Seo JS, Yang TH, Kim DK, et al. Meta-analysis of cytochrome p450 2c19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. Am J Cardiol. 2012;110:502–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Frere C, Cuisset T, Gaborit B, Alessi MC, Hulot JS. The cyp2c19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-st acute coronary syndrome. J Thromb Haemost. 2009;7:1409–11.CrossRefPubMedGoogle Scholar
  30. 30.
    Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, et al. Cytochrome 2c19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010;121:512–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Chen L, Qin S, Xie J, Tang J, Yang L, Shen W, et al. Genetic polymorphism analysis of cyp2c19 in chinese han populations from different geographic areas of mainland china. Pharmacogenomics. 2008;9:691–702.CrossRefPubMedGoogle Scholar
  32. 32.
    Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthelemy O, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome p450 2c19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol. 2010;56:134–43.CrossRefPubMedGoogle Scholar
  33. 33.
    Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, et al. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the princ (plavix response in coronary intervention) trial. JACC Cardiovasc Interv. 2008;1:620–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Soranzo N, Rendon A, Gieger C, Jones CI, Watkins NA, Menzel S, et al. A novel variant on chromosome 7q22.3 associated with mean platelet volume, counts, and function. Blood. 2009;113:3831–7.CrossRefPubMedCentralPubMedGoogle Scholar
  35. 35.
    Martin JF, Bath PM, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet. 1991;338:1409–11.CrossRefPubMedGoogle Scholar
  36. 36.
    Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost. 2010;8:148–56.CrossRefPubMedCentralPubMedGoogle Scholar
  37. 37.
    Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.CrossRefPubMedGoogle Scholar
  38. 38.
    Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15.CrossRefPubMedGoogle Scholar
  39. 39.
    Postula M, Kaplon-Cieslicka A, Rosiak M, Kondracka A, Serafin A, Filipiak KJ, et al. Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: evaluation of 27 polymorphisms within candidate genes. J Thromb Haemost. 2011;9:2291–301.CrossRefPubMedGoogle Scholar
  40. 40.
    Hobson AR, Petley G, Morton G, Dawkins KD, Curzen NP. Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with drug-eluting stent thrombosis whilst on dual antiplatelet therapy. Thromb J. 2008;6:1.CrossRefPubMedCentralPubMedGoogle Scholar
  41. 41.
    Gluckman TJ, McLean RC, Schulman SP, Kickler TS, Shapiro EP, Conte JV, et al. Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery. J Am Coll Cardiol. 2011;57:1069–77.CrossRefPubMedCentralPubMedGoogle Scholar
  42. 42.
    Campo G, Fileti L, de Cesare N, Meliga E, Furgieri A, Russo F, et al. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: A 3t/2r (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. J Am Coll Cardiol. 2010;56:1447–55.CrossRefPubMedGoogle Scholar
  43. 43.
    Frelinger 3rd AL, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, et al. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation. 2009;120:2586–96.CrossRefPubMedGoogle Scholar
  44. 44.
    Bouman HJ, Schomig E, van Werkum JW, Velder J, Hackeng CM, Hirschhauser C, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med. 2011;17:110–6.CrossRefPubMedGoogle Scholar
  45. 45.
    Price MJ, Murray SS, Angiolillo DJ, Lillie E, Smith EN, Tisch RL, et al. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the gift (genotype information and functional testing) study. J Am Coll Cardiol. 2012;59:1928–37.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Hanbin Cui
    • 1
  • Shaoyi Lin
    • 1
  • Xiaomin Chen
    • 1
  • Wenhui Gao
    • 1
  • Xiaojing Li
    • 1
  • Honglin Zhou
    • 1
  • Weiping Du
    • 1
  • Shenghuang Wang
    • 1
  • Ruochi Zhao
    • 1
  1. 1.Cardiology Center, Ningbo First HospitalNingbo UniversityNingboPeople’s Republic of China

Personalised recommendations